BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy 2017;37:1150-63. [PMID: 28672100 DOI: 10.1002/phar.1982] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Wen YF, Culhane-Pera KA, Thyagarajan B, Bishop JR, Zierhut H, Lo M, Xiong T, Peng K, Holzer K, Lee K, Straka RJ. Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. Pharmacotherapy 2020;40:142-52. [PMID: 31884695 DOI: 10.1002/phar.2360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kim JH, Yee J, Chang BC, Gwak HS. Gene Polymorphisms of the Renin-Angiotensin System and Bleeding Complications of Warfarin: Genetic-Based Machine Learning Models. Pharmaceuticals (Basel) 2021;14:824. [PMID: 34451921 DOI: 10.3390/ph14080824] [Reference Citation Analysis]
3 Loresto FL Jr, Welton J, Grim S, Valdez C, Eron K. Exploring Inpatient Medication Patterns: A Big Data and Multilevel Approach. J Nurs Adm 2019;49:336-42. [PMID: 31135641 DOI: 10.1097/NNA.0000000000000762] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Shah RR, Gaedigk A. Precision medicine: does ethnicity information complement genotype-based prescribing decisions? Ther Adv Drug Saf 2018;9:45-62. [PMID: 29318005 DOI: 10.1177/2042098617743393] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
5 Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Calderón-Ospina CA, Peña N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ. Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients. Pharmgenomics Pers Med 2018;11:169-78. [PMID: 30410385 DOI: 10.2147/PGPM.S170515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang C, Lei J, Liu Y, Wang Y, Huang L, Feng Y. Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China. Front Pharmacol 2021;12:754380. [PMID: 34795589 DOI: 10.3389/fphar.2021.754380] [Reference Citation Analysis]
7 Zgheib NK, Patrinos GP, Akika R, Mahfouz R. Precision Medicine in Low‐ and Middle‐Income Countries. Clin Pharmacol Ther 2019;107:29-32. [DOI: 10.1002/cpt.1649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
8 Anand A, Kumar R, Gupta A, Vijayvergiya R, Mehrotra S, Lad D, Barwad P, Sharma S, Patil AN. Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: a cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting. Indian Heart Journal 2022. [DOI: 10.1016/j.ihj.2022.03.008] [Reference Citation Analysis]
9 Gao W, Li Z, Chen W, Zhang S. Performance Evaluation of Warfarin Dose Prediction Algorithms and Effects of Clinical Factors on Warfarin Dose in Chinese Patients. Ther Drug Monit 2021;43:527-35. [PMID: 34250965 DOI: 10.1097/FTD.0000000000000880] [Reference Citation Analysis]
10 Asiimwe IG, Pirmohamed M. Ethnic Diversity and Warfarin Pharmacogenomics. Front Pharmacol 2022;13:866058. [PMID: 35444556 DOI: 10.3389/fphar.2022.866058] [Reference Citation Analysis]
11 Zhu Y, Xu C, Liu J. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation. J Clin Pharm Ther 2020;45:1466-73. [PMID: 32710457 DOI: 10.1111/jcpt.13218] [Reference Citation Analysis]
12 Zhu Y, Moriarty JP, Swanson KM, Takahashi PY, Bielinski SJ, Weinshilboum R, Wang L, Borah BJ. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet Med 2021;23:461-70. [PMID: 33041335 DOI: 10.1038/s41436-020-00995-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mak M, Lam C, Pineda SJ, Lou M, Xu LY, Meeks C, Lin C, Stone R, Rodgers K, Mitani G. Pharmacogenetics of Warfarin in a Diverse Patient Population. J Cardiovasc Pharmacol Ther 2019;24:521-33. [PMID: 31064211 DOI: 10.1177/1074248419843530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Sasano M, Ohno M, Fukuda Y, Nonen S, Hirobe S, Maeda S, Miwa Y, Yokoyama J, Nakayama H, Miyagawa S, Sawa Y, Fujio Y, Maeda M. Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients. Eur J Clin Pharmacol 2019;75:901-11. [DOI: 10.1007/s00228-019-02656-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Li D, Xie AH, Liu Z, Li D, Ning B, Thakkar S, Tong W, Xu J. Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations. Pharmaceutics 2020;12:E1021. [PMID: 33113799 DOI: 10.3390/pharmaceutics12111021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Scheinfeldt LB, Brangan A, Kusic DM, Kumar S, Gharani N. Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants. J Pers Med 2021;11:131. [PMID: 33669176 DOI: 10.3390/jpm11020131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Holail J, Mobarak R, Al-Ghamdi B, Aljada A, Fakhoury H. Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. Drug Metab Pers Ther 2022. [PMID: 35365981 DOI: 10.1515/dmdi-2022-0108] [Reference Citation Analysis]
18 Giles JB, Miller EC, Steiner HE, Karnes JH. Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches. Front Pharmacol 2022;12:812830. [DOI: 10.3389/fphar.2021.812830] [Reference Citation Analysis]
19 Ayesh BM, Abu Shaaban AS, Abed AA. Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine. Future Sci OA 2018;4:FSO276. [PMID: 29568565 DOI: 10.4155/fsoa-2017-0112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yang S, Dou X, Wang Z, Zhang W, Ding K, Meng W, Li H, Liu J, Liu Y, Jin T. Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research. Mol Genet Genomics 2022. [PMID: 35146537 DOI: 10.1007/s00438-022-01855-9] [Reference Citation Analysis]
21 Steiner HE, Giles JB, Patterson HK, Feng J, El Rouby N, Claudio K, Marcatto LR, Tavares LC, Galvez JM, Calderon-Ospina CA, Sun X, Hutz MH, Scott SA, Cavallari LH, Fonseca-Mendoza DJ, Duconge J, Botton MR, Santos PCJL, Karnes JH. Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Front Pharmacol 2021;12:749786. [PMID: 34776967 DOI: 10.3389/fphar.2021.749786] [Reference Citation Analysis]
22 Sun B, Wen YF, Culhane-Pera KA, Lo M, Xiong T, Lee K, Peng K, Thyagarajan B, Bishop JR, Zierhut H, Straka RJ. Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms. Pharmacotherapy 2021;41:265-76. [PMID: 33202062 DOI: 10.1002/phar.2487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Bharti N, Banerjee R, Achalere A, Kasibhatla SM, Joshi R. Genetic diversity of 'Very Important Pharmacogenes' in two South-Asian populations. PeerJ 2021;9:e12294. [PMID: 34824904 DOI: 10.7717/peerj.12294] [Reference Citation Analysis]
24 Blizinsky KD, Bonham VL. Leveraging the Learning Health Care Model to Improve Equity in the Age of Genomic Medicine. Learn Health Syst 2018;2:e10046. [PMID: 29457138 DOI: 10.1002/lrh2.10046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
25 Bollati V, Ferrari L, Leso V, Iavicoli I. Personalised Medicine: implication and perspectives in the field of occupational health. Med Lav 2020;111:425-44. [PMID: 33311418 DOI: 10.23749/mdl.v111i6.10947] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Leary E, Brilliant M, Peissig P, Griesbach S. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center. Am J Health Syst Pharm 2019;76:387-97. [PMID: 31415684 DOI: 10.1093/ajhp/zxy072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
27 Hooker SE Jr, Woods-Burnham L, Bathina M, Lloyd S, Gorjala P, Mitra R, Nonn L, Kimbro KS, Kittles RA. Genetic Ancestry Analysis Reveals Misclassification of Commonly Used Cancer Cell Lines. Cancer Epidemiol Biomarkers Prev 2019;28:1003-9. [PMID: 30787054 DOI: 10.1158/1055-9965.EPI-18-1132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Dainis AM, Ashley EA. Cardiovascular Precision Medicine in the Genomics Era. JACC Basic Transl Sci 2018;3:313-26. [PMID: 30062216 DOI: 10.1016/j.jacbts.2018.01.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
29 Zhao L, Wang J, Shi S, Wu Y, Liu J, He S, Zou Y, Xie H, Ge S, Ye H. Plasma miRNA profiles associated with stable warfarin dosage in Chinese patients. PeerJ 2020;8:e9995. [PMID: 33083118 DOI: 10.7717/peerj.9995] [Reference Citation Analysis]
30 Roda A, Michelini E, Caliceti C, Guardigli M, Mirasoli M, Simoni P. Advanced bioanalytics for precision medicine. Anal Bioanal Chem 2018;410:669-77. [PMID: 29026940 DOI: 10.1007/s00216-017-0660-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
31 Colet C, Botton MR, Schwambach KH, Amador TA, Heineck I. Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil. J Vasc Bras 2021;20:e20200214. [PMID: 34104133 DOI: 10.1590/1677-5449.200214] [Reference Citation Analysis]
32 Reyes-González S, de Las Barreras C, Reynaldo G, Rodríguez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther 2020:/j/dmdi. [PMID: 32809952 DOI: 10.1515/dmdi-2020-0135] [Reference Citation Analysis]
33 Zhang RF, Ma CM, Wang N, Yang MH, Li WW, Yin XM, Dong YX, Yu XH, Xiao XJ, Xia YL, Gao LJ. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. BMC Cardiovasc Disord 2021;21:214. [PMID: 33906609 DOI: 10.1186/s12872-021-02032-3] [Reference Citation Analysis]
34 Li W, Zhao P, Chen L, Lai X, Shi G, Li L, Dong J. Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients. Pharmacogenomics 2020;21:101-10. [PMID: 31854268 DOI: 10.2217/pgs-2019-0139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
35 Langaee T, El Rouby N, Stauffer L, Galloway C, Cavallari LH. Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. Genetic Testing and Molecular Biomarkers 2019;23:209-14. [DOI: 10.1089/gtmb.2018.0298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci 2021;14:268-76. [PMID: 32860733 DOI: 10.1111/cts.12854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Shendre A, Dillon C, Limdi NA. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics 2018;19:1357-71. [PMID: 30345882 DOI: 10.2217/pgs-2018-0146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
38 Wang X, Tang B, Zhou M, Liu L, Feng X, Wang X, Qiu K. Efficacy and safety of genotype-guided warfarin dosing versus non-genotype-guided warfarin dosing strategies: A systematic review and meta-analysis of 27 randomized controlled trials. Thromb Res 2021;210:42-52. [PMID: 34999431 DOI: 10.1016/j.thromres.2021.12.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]